The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London close: Spain in focus after bailout rumours

Fri, 08th Jun 2012 16:37

- Spanish bailout could be on the cards- Fitch downgrades Spain to BBB- Investors look ahead of Chinese data this weekendRumours about an imminent recapitalisation of Spain's banking sector and concerns over global growth were doing the rounds on Friday, yet the Footsie still managed to pare losses by the close.According to a Financial Times article this afternoon, Spain may ask for bailout aid for its financial sector as early as tomorrow during a conference call with European finance ministers.Fitch Ratings said last night that the "likely 'fiscal cost'" of restructuring and recapitalising the Spanish banking sector would be between €60bn and €100bn in a worst-case scenario. This came as the ratings agency downgraded its sovereign debt rating for the country from A to BBB. Also weighing on sentiment today were yesterday's comments from Federal Reserve Chairman Ben Bernanke who "performed his usual trick of depressing the markets", according to Craig Erlam from Alpari. Analysts were hoping for hints of imminent stimulus measures but Bernanke failed to say whether the Fed would be embarking on QE3 any time soon. "The positive sentiment from earlier in the week has been knocked over the last 24 hours. With the ECB, BOE and Fed all deciding against further QE or rate cuts this week, it's surprising that the markets have held up as well as they have," Erlam said in an emailed note.This afternoon, President Barack Obama said that the ongoing crisis in Europe could have a "potential impact" on the US economy as he urged Eurozone leaders to act: "The sooner they act the more decisive and concrete their action, the sooner people and markets will regain some confidence."Investors will still be digesting the recent interest rate cut from China, which initially spurred impressive gains for equity markets on Thursday. However, ahead of some key inflation and industrial production figures due out this weekend from the world's second-largest economy, some analysts are questioning whether the rate cut was a pre-emptive move ahead of what could be some disappointing data. FTSE 100: Miners down, defensives upVedanta, Kazakhmys, Antofagasta, Xstrata, Rio Tinto, Glencore and ENRC were among the worst performers of the day as investors fled from risk. BHP Billiton was also among the fallers after Bank of America Merrill-Lynch reduced its profit forecasts for the group on the back of lower oil prices estimates. Kazakhmys announced late on that it has signed an agreement with JSC RusHydro, one of Russia's largest power generating companies, to consider establishing a hydro-electric power joint venture. The defensive utilities sector benefited from its 'safe-haven' appeal today with Severn Trent, Centrica, United Utilities, SSE and National Grid making gains. Credit Suisse raised its target price for National Grid today after saying that Ofgem's new RIIO regulation presents a £2.5bn opportunity for the group.Capita was a strong performer after JP Morgan Cazenove reiterated its overweight rating on the outsourcing giant.Pharmaceuticals leviathan GlaxoSmithkline was also in demand after extending the offer period for its hostile take-over of US sector peer Human Genome Sciences (HGS) by a further three weeks.FTSE 250: Bumi leaps on mining contractMining firm Bumi leapt into the top spot on the second-tier index after reportedly signing a contract to sell 50m metric tons of coal. According to Dow Jones Newswires, the coal will be sold at an average price of $80 per ton this calendar year. The firm's Resource Director, Dileep Srivastava, was quoted as saying: "The sales contract is 67% of our 75-million-ton output guidance for 2012." Heading the other way was energy markets-focused engineer Lamprell which was battered after sneaking out a profit warning on Thursday after the London market closed, saying that it now expects to make a half-year loss of between $15m and $20m, compared with earlier guidance of "a small loss". The group also said that Chairman Jonathan Silver would step down. "We continue to believe that management's credibility has fundamentally deteriorated," Nomura said in a research note this morning.FTSE 100 - RisersCapita (CPI) 649.50p +2.85%Severn Trent (SVT) 1,782.00p +2.71%Centrica (CNA) 315.20p +2.20%British Sky Broadcasting Group (BSY) 696.00p +2.20%Standard Life (SL.) 220.40p +1.90%United Utilities Group (UU.) 680.50p +1.80%Vodafone Group (VOD) 171.50p +1.51%Shire Plc (SHP) 1,879.00p +1.51%Kingfisher (KGF) 279.00p +1.31%Reed Elsevier (REL) 493.40p +1.31%FTSE 100 - FallersVedanta Resources (VED) 935.50p -5.07%Rio Tinto (RIO) 2,869.00p -4.84%Eurasian Natural Resources Corp. (ENRC) 423.80p -3.94%Evraz (EVR) 279.20p -3.19%Kazakhmys (KAZ) 705.00p -3.16%BHP Billiton (BLT) 1,767.00p -2.91%Anglo American (AAL) 2,074.00p -2.77%Petrofac Ltd. (PFC) 1,535.00p -2.66%Schroders (Non-Voting) (SDRC) 976.00p -2.59%Antofagasta (ANTO) 1,060.00p -2.21%FTSE 250 - RisersBumi (BUMI) 365.00p +11.93%Atkins (WS) (ATK) 694.50p +6.27%New World Resources A Shares (NWR) 326.10p +4.19%Bellway (BWY) 770.50p +3.56%Ophir Energy (OPHR) 615.00p +3.36%Grainger (GRI) 90.00p +2.97%Synergy Health (SYR) 887.00p +2.60%RPS Group (RPS) 202.00p +2.54%Bovis Homes Group (BVS) 432.30p +2.32%Brown (N.) Group (BWNG) 233.60p +1.96%FTSE 250 - FallersLamprell (LAM) 84.50p -22.26%Kesa Electricals (KESA) 49.81p -7.93%Afren (AFR) 108.40p -7.51%Lonmin (LMI) 747.50p -5.62%Essar Energy (ESSR) 117.40p -5.55%Anglo Pacific Group (APF) 238.80p -5.50%Ocado Group (OCDO) 94.90p -5.10%Imagination Technologies Group (IMG) 487.80p -4.17%Avocet Mining (AVM) 157.00p -3.98%Hays (HAS) 72.25p -3.73%BC
More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.